Alkem Laboratories Limited (NSE:ALKEM)

Market Cap	614.92B -6.4%
Revenue (ttm)	150.81B +13.4%
Net Income	21.58B -5.6%
EPS	180.45 -5.6%
Shares Out	119.57M
PE Ratio	28.38
Forward PE	25.75
Dividend	53.00 (1.03%)
Ex-Dividend Date	Aug 7, 2026

Volume	58
Open	5,138.50
Previous Close	5,120.50
Day's Range	5,138.50 - 5,143.00
52-Week Range	5,051.00 - 5,933.50
Beta	0.29
Analysts	Buy
Price Target	6,002.55 (+16.71%)
Est. Earnings	Nov 6, 2026

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumato...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 19,346
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALKEM

Financial Performance

In fiscal year 2026, Alkem Laboratories's revenue was 147.12 billion, an increase of 13.48% compared to the previous year's 129.65 billion. Earnings were 23.02 billion, an increase of 6.30%.

Analyst Summary

According to 20 analysts, the average rating for ALKEM stock is "Buy." The 12-month stock price target is ₹6,003, which is an increase of 16.71% from the latest price.

Price Target

₹6,003

(16.71% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error